Objective: To date there is no firm conclusion as to the efficacy and safety of ibuprofen compared with indomethacin for patent ductus arteriosus (PDA) closure in extremely premature infants. We conducted a randomized controlled trial to better address this issue.
Methods: One hundred and nineteen infants (gestational age ≤ 28 weeks) with respiratory distress syndrome and PDA confirmed by echocardiography were randomly assigned to receive either indomethacin (0.2 mg/kg) or ibuprofen (10 mg/kg), starting at < 24 h of life, followed by doses of half the first dose within 48 hours at 24-hour intervals if indicated by echocardiographic PDA flow pattern.
Results: The PDA closure rate and the doses of drug (mean ± SD) were similar in both groups: 53/60 (88.3%) and 1.9 ± 1.5 in infants given ibuprofen, and 52/59 (88.1 %) and 1.9 ± 1.7 in infants given indomethacin. There was no significant difference in the numbers of infants requiring surgical ligation, and the levels of post-treatment serum creatinine and urea nitrogen between the two groups. Although not significantly different, more infants (9/59 [15.3%]) treated with indomethacin tended to develop oliguria (< 1 ml/kg/h) than those treated with ibuprofen (4/60 [6.7%]). There were no significant differences in side effects or complications between the two groups.
Conclusions: Ibuprofen is as effective as indomethacin for the early-targeted PDA treatment in extremely premature infants, without increasing the incidence of complications. Using our echocardiographic PDA flow pattern as a guide for PDA treatment, we used fewer doses of drugs to achieve acceptable closing rates.
- extremely premature infant
- patent ductus arteriosus
Statistics from Altmetric.com
Re: paper by Su et al. on ibuprofen vs indometacin for treatment of PDA (ADC 2008;93:F94-F99). There is an error in the first sentence of the results section in the abstract. In two places "mg/kg" should be omitted.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.